Characteristics of the study cohort
| Characteristics . | All patients . | Sclerosis . | |
|---|---|---|---|
| Present . | Absent . | ||
| (N = 847) . | (N = 198) . | (N = 649) . | |
| Patient age at transplantation, y | |||
| Median | 48 | 49 | 48 |
| Range | 1-78 | 2-69 | 1-78 |
| Donor-recipient gender combination, no. (%) | |||
| Male to male | 272 (32) | 66 (33) | 206 (32) |
| Male to female | 153 (18) | 33 (17) | 120 (18) |
| Female to male | 230 (27) | 42 (21) | 188 (29) |
| Female to female | 192 (23) | 57 (29) | 135 (21) |
| Patient race, no. (%) | |||
| White | 694 (82) | 171 (86) | 523 (81) |
| Others | 126 (15) | 19 (10) | 107 (16) |
| Unknown | 27 (3) | 8 (4) | 19 (3) |
| Diagnosis, no. (%) | |||
| Acute leukemia | 363 (43) | 86 (43) | 277 (43) |
| CML | 99 (12) | 19 (10) | 80 (12) |
| MDS or MPN | 201 (24) | 45 (23) | 156 (24) |
| CLL | 39 (5) | 9 (5) | 30 (5) |
| Malignant lymphoma or MM | 145 (17) | 39 (20) | 106 (16) |
| Disease risk at the time of transplantation,*no. (%) | |||
| Low risk | 316 (37) | 69 (35) | 247 (38) |
| High risk | 531 (63) | 129 (65) | 402 (62) |
| Stem cell graft source, no. (%) | |||
| Bone marrow | 102 (12) | 14 (7) | 88 (14) |
| Mobilized blood cells | 745 (88) | 184 (93) | 561 (86) |
| HLA and donor type,†no. (%) | |||
| HLA-matched related | 374 (44) | 91 (46) | 283 (44) |
| HLA-matched unrelated | 326 (38) | 86 (43) | 240 (37) |
| HLA-mismatched related | 13 (2) | 1 (1) | 12 (2) |
| HLA-mismatched unrelated | 134 (16) | 20 (10) | 114 (18) |
| ABO compatibility, no. (%) | |||
| Match | 472 (56) | 117 (59) | 355 (55) |
| Minor mismatch | 170 (20) | 48 (24) | 122 (19) |
| Major mismatch | 205 (24) | 33 (17) | 172 (27) |
| Intensity of conditioning regimen, no. (%) | |||
| High intensity | 601 (71) | 132 (67) | 469 (72) |
| Reduced intensity | 246 (29) | 66 (33) | 180 (28) |
| TBI dose in conditioning regimen, no. (%) | |||
| None | 348 (41) | 67 (34) | 281 (43) |
| ≤450 cGy | 297 (35) | 78 (39) | 219 (34) |
| >450 cGy | 202 (24) | 53 (27) | 149 (23) |
| Prior grade 2-4 acute GVHD, no. (%) | 619 (73) | 137 (69) | 482 (74) |
| Characteristics . | All patients . | Sclerosis . | |
|---|---|---|---|
| Present . | Absent . | ||
| (N = 847) . | (N = 198) . | (N = 649) . | |
| Patient age at transplantation, y | |||
| Median | 48 | 49 | 48 |
| Range | 1-78 | 2-69 | 1-78 |
| Donor-recipient gender combination, no. (%) | |||
| Male to male | 272 (32) | 66 (33) | 206 (32) |
| Male to female | 153 (18) | 33 (17) | 120 (18) |
| Female to male | 230 (27) | 42 (21) | 188 (29) |
| Female to female | 192 (23) | 57 (29) | 135 (21) |
| Patient race, no. (%) | |||
| White | 694 (82) | 171 (86) | 523 (81) |
| Others | 126 (15) | 19 (10) | 107 (16) |
| Unknown | 27 (3) | 8 (4) | 19 (3) |
| Diagnosis, no. (%) | |||
| Acute leukemia | 363 (43) | 86 (43) | 277 (43) |
| CML | 99 (12) | 19 (10) | 80 (12) |
| MDS or MPN | 201 (24) | 45 (23) | 156 (24) |
| CLL | 39 (5) | 9 (5) | 30 (5) |
| Malignant lymphoma or MM | 145 (17) | 39 (20) | 106 (16) |
| Disease risk at the time of transplantation,*no. (%) | |||
| Low risk | 316 (37) | 69 (35) | 247 (38) |
| High risk | 531 (63) | 129 (65) | 402 (62) |
| Stem cell graft source, no. (%) | |||
| Bone marrow | 102 (12) | 14 (7) | 88 (14) |
| Mobilized blood cells | 745 (88) | 184 (93) | 561 (86) |
| HLA and donor type,†no. (%) | |||
| HLA-matched related | 374 (44) | 91 (46) | 283 (44) |
| HLA-matched unrelated | 326 (38) | 86 (43) | 240 (37) |
| HLA-mismatched related | 13 (2) | 1 (1) | 12 (2) |
| HLA-mismatched unrelated | 134 (16) | 20 (10) | 114 (18) |
| ABO compatibility, no. (%) | |||
| Match | 472 (56) | 117 (59) | 355 (55) |
| Minor mismatch | 170 (20) | 48 (24) | 122 (19) |
| Major mismatch | 205 (24) | 33 (17) | 172 (27) |
| Intensity of conditioning regimen, no. (%) | |||
| High intensity | 601 (71) | 132 (67) | 469 (72) |
| Reduced intensity | 246 (29) | 66 (33) | 180 (28) |
| TBI dose in conditioning regimen, no. (%) | |||
| None | 348 (41) | 67 (34) | 281 (43) |
| ≤450 cGy | 297 (35) | 78 (39) | 219 (34) |
| >450 cGy | 202 (24) | 53 (27) | 149 (23) |
| Prior grade 2-4 acute GVHD, no. (%) | 619 (73) | 137 (69) | 482 (74) |
CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm.
The low-risk category included CML in chronic phase, acute leukemia in first remission, MDS without excess blasts, and aplastic anemia. The high-risk category included all other diseases and stages.
Recipient HLA-matching with the donor, as determined by methods informative for 4-digit resolution of HLA-A, B, C, DRB1, and DQB1 alleles. In 14 pairs, matching was determined by methods informative for 2-digit resolution of one or more HLA-A, B, or C alleles.